Cargando…
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
AIMS: SARS–CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19. METHODS: Virus binds to the cell surface receptor ACE2; indeed, recen...
Autores principales: | Solerte, Sebastiano Bruno, Di Sabatino, Antonio, Galli, Massimo, Fiorina, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275134/ https://www.ncbi.nlm.nih.gov/pubmed/32506195 http://dx.doi.org/10.1007/s00592-020-01539-z |
Ejemplares similares
-
Reply to letter to the editor regarding “Use of DPP-4 inhibitors in patients with COVID-19”
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020) -
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022) -
Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013) -
Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015) -
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)